`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE SOUTHERN DISTRICT OF INDIANA
`
`))
`
`))
`
`))
`
`))
`
`) Civil Action No. 1:10 cv-1376 TWP-DKL
`)
`)
`TEVA PARENTERAL MEDICINES, INC.,
`)
`APP PHARMACEUTICALS, LLC,
`)
`PLIVA HRVATSKA D.O.O.,
`TEVA PHARMACEUTICALS USA, INC., and )
`BARR LABORATORIES, INC.,
`
`ELI LILLY AND COMPANY,
`
`Plaintiff,
`
`v.
`
`Defendants.
`
`AMENDED JOINT CLAIM CONSTRUCTION STATEMENT
`
`Pursuant to the Court’s April 12, 2012, Entry in Preparation for Markman Hearing
`
`(ECF No. 109), Plaintiff Eli Lilly and Company (“Lilly”) and Defendants Teva Parenteral
`
`Medicines, Inc., APP Pharmaceuticals, LLC, Pliva Hrvatska d.o.o., Teva Pharmaceuticals USA,
`
`Inc., and Barr Laboratories, Inc. (collectively “Defendants”) hereby submit the following
`
`Amended Joint Claim Construction Statement.
`
`(a)
`
`The parties have exchanged lists of the claim terms, phrases, or clauses
`
`which they believe require construction, as well as proposed constructions. The parties have
`
`agreed upon the following constructions:
`
`Claim Term/Phrase
`
`Construction
`
`“an effective amount of folic acid and
`an effective amount of a methylmalonic
`acid lowering agent”
`
`“amounts of folic acid and a
`methylmalonic acid lowering agent that
`are capable of reducing the prevalence
`or severity of one or more toxicities
`associated with the administration of
`pemetrexed disodium”
`
`Wockhardt Exhibit 1026 - 1
`
`
`
`Case 1:10-cv-01376-TWP-DKL Document 110 Filed 04/19/12 Page 2 of 3 PageID #: 2013
`
`“methylmalonic acid lowering agent”
`
`“an effective amount of pemetrexed
`disodium”
`
`“an agent such as vitamin B12 which
`can be used to lower the concentration
`of methylmalonic acid in a mammal”
`
`“an amount of pemetrexed disodium
`that is capable of providing a
`therapeutic benefit to the patient in
`need thereof”
`
`The parties have also agreed that the preambles of claims 1 and 12 are limiting.
`
`(b)
`
`The following chart reflects Plaintiff’s and Defendants’ proposed
`
`constructions for the claim terms, phrases, or clauses identified by one or more of the parties as
`
`requiring construction:
`
`Claim Term/Phrase
`
`Plaintiff’s Proposed
`Construction
`
`Defendants’ Proposed
`Construction
`
`“patient”
`
`“patient (i.e., a human under
`medical care)”
`
`“vitamin B12”
`
`“vitamin B12 (i.e.,
`cyanocobalamin)”
`
`“mammal”
`
`Indefinite
`
`(c)
`
`The parties anticipate that less than one day will be needed for the
`
`Markman hearing.
`
`(d)
`
`(e)
`
`The parties will not call any witnesses at the Markman hearing.
`
`The parties will first address the “patient” claim term (with a background
`
`introduction) and then will address the “vitamin B12” claim term, with Plaintiff going first for
`
`each issue.
`
`2
`
`Wockhardt Exhibit 1026 - 2
`
`
`
`Case 1:10-cv-01376-TWP-DKL Document 110 Filed 04/19/12 Page 3 of 3 PageID #: 2014
`
`/s/ Jan M. Carroll
`Jan M. Carroll, No. 4187-49
`BARNES & THORNBURG LLP
`11 South Meridian Street
`Indianapolis, Indiana 46204
`(317) 236-1313
`jan.caroll@btlaw.com
`
`OF COUNSEL:
`Bruce R. Genderson
`Adam L. Perlman
`Ellen E. Oberwetter
`Dov P. Grossman
`David M. Krinsky
`Megan A. Hughes
`WILLIAMS & CONNOLLY LLP
`725 Twelfth Street, N.W.
`Washington, DC 20005
`(202) 434-5000 (telephone)
`(202) 434-5029 (facsimile)
`
`Attorneys for Plaintiff
`Eli Lilly and Company
`
`Respectfully submitted,
`
`/s/ Kandi Kilkelly Hidde (w/permission)
`David O. Tittle, # 857-49
`Kandi Kilkelly Hidde, #18033-49
`BINGHAM McHALE LLP
`2700 Market Tower
`10 W. Market Street
`Indianapolis, Indiana 46204-4900
`Phone:(317) 635-8900
`Fax:
`(317) 236-9907
`dtittle@binghammchale.com
`khidde@binghammchale.com
`
`OF COUNSEL:
`Daryl L. Wiesen
`Emily L. Rapalino
`GOODWIN PROCTER LLP
`53 State Street
`Boston, MA 02109
`Tel: (617) 570-1000
`dwiesen@goodwinprocter.com
`erapalino@goodwinprocter.com
`
`Michael B. Cottler
`Jonathan E. Grossman
`Eric H. Yecies
`GOODWIN PROCTER LLP
`620 Eighth Avenue
`New York, NY 10018
`Tel: (212) 813-8800
`mcottler@goodwinprocter.com
`jgrossman@goodwinprocter.com
`eyecies@goodwinprocter.com
`
`Attorneys for Defendants Teva Parenteral
`Medicines, Inc., APP Pharmaceuticals, LLC,
`Pliva Hrvatska d.o.o., Teva Pharmaceuticals
`USA, Inc. and Barr Laboratories, Inc.
`
`INDS02 JMC 1216665v1
`
`3
`
`Wockhardt Exhibit 1026 - 3